BCAL Diagnostics Past Earnings Performance

Past criteria checks 0/6

BCAL Diagnostics's earnings have been declining at an average annual rate of -44.4%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been growing at an average rate of 55% per year.

Key information

-44.4%

Earnings growth rate

-34.1%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate55.0%
Return on equity-74.5%
Net Margin-206.6%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?

Aug 08
Is BCAL Diagnostics (ASX:BDX) In A Good Position To Deliver On Growth Plans?

Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In Growth

Apr 07
Companies Like BCAL Diagnostics (ASX:BDX) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn Situation

Dec 23
Here's Why We're Not Too Worried About BCAL Diagnostics' (ASX:BDX) Cash Burn Situation

Revenue & Expenses Breakdown

How BCAL Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:BDX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 243-644
31 Mar 243-644
31 Dec 234-544
30 Sep 233-534
30 Jun 233-534
31 Mar 232-534
31 Dec 221-523
30 Sep 221-423
30 Jun 221-322
31 Mar 221-312
31 Dec 211-312
30 Sep 210-211
30 Jun 210-211
31 Mar 210-110
31 Dec 201010
30 Sep 200-110
30 Jun 200-110
30 Jun 190000
30 Jun 180000

Quality Earnings: BDX is currently unprofitable.

Growing Profit Margin: BDX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BDX is unprofitable, and losses have increased over the past 5 years at a rate of 44.4% per year.

Accelerating Growth: Unable to compare BDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: BDX has a negative Return on Equity (-74.52%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:00
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BCAL Diagnostics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Rosemary CumminsMST Financial Services Pty Limited